Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

Por Sonesson, Christian, Johansson, Peter A., Johnsson, Eva, Gause-Nilsson, Ingrid
Publicado no Cardiovasc Diabetol (2016)

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis

Por Yavin, Yshai, Mansfield, Traci A., Ptaszynska, Agata, Johnsson, Kristina, Parikh, Shamik, Johnsson, Eva
Publicado no Diabetes Ther (2016)

Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies

Por Fioretto, Paola, Mansfield, Traci A., Ptaszynska, Agata, Yavin, Yshai, Johnsson, Eva, Parikh, Shamik
Publicado no Drugs Aging (2016)

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Por Fioretto, Paola, Stefansson, Bergur V., Johnsson, Eva, Cain, Valerie A., Sjöström, C. David
Publicado no Diabetologia (2016)

Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16‐week double‐blind treatment per...

Por Araki, Eiichi, Onishi, Yukiko, Asano, Michiko, Kim, Hyosung, Ekholm, Ella, Johnsson, Eva, Yajima, Toshitaka
Publicado no J Diabetes Investig (2016)

Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a ‘Case Study’

Por Ptaszynska, Agata, Cohen, Samuel M., Messing, Edward M., Reilly, Timothy P., Johnsson, Eva, Johnsson, Kristina
Publicado no Diabetes Ther (2015)

Dapagliflozin once‐daily and exenatide once‐weekly dual therapy: A 24‐week randomized, placebo‐controlled, phase II study examining effects on body weight and prediabetes in obese...

Por Lundkvist, Per, Sjöström, C. David, Amini, Sam, Pereira, Maria J., Johnsson, Eva, Eriksson, Jan W.
Publicado no Diabetes Obes Metab (2016)